Abbott
Executive Summary
Files NDA for Sevorane (sevoflurane)inhalation anesthetic "for induction and maintenance of general anesthesia in adult and pediatric patients for both inpatient and outpatient surgery," the company announces. Abbott says the drug has been studied "as part of worldwide clinical trials involving more than 6,000 patients that suggest that the drug provides smooth and rapid induction of anesthesia and fast emergence, recovery and discharge"
Files NDA for Sevorane (sevoflurane)inhalation anesthetic "for induction and maintenance of general anesthesia in adult and pediatric patients for both inpatient and outpatient surgery," the company announces. Abbott says the drug has been studied "as part of worldwide clinical trials involving more than 6,000 patients that suggest that the drug provides smooth and rapid induction of anesthesia and fast emergence, recovery and discharge". |